ClinicaliQ Trial Snapshot
- A Study of Brenipatide (LY3537031) in Participants With Irritable Bowel Syndrome-Diarrhea (IBS-D) — Recruiting • Phase II • Dermatology • NCT07545759.
- A 35-week trial testing whether brenipatide injections improve symptoms and are safe in patients with IBS-diarrhea compared to placebo.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
The purpose of this study is to evaluate how well brenipatide (LY3537031) is tolerated, what side effects may occur, and the safety and efficacy in participants with Irritable Bowel Syndrome-Diarrhea (IBS-D). The study drug will be administered subcutaneously (SC) (under the skin) when compared with placebo. The study will last approximately 35 weeks. Conditions: Irritable Bowel Syndrome, Diarrhea Interventions: LY3537031, Placebo Lead Sponsor: Eli Lilly and Company Planned Enrollment: 531 participants